SBIR/STTR Research Award

Catheter Development for Epicardial Atrial Gene Painting

Award identifier f43df362fdd6622df08151c78ad60c8d3727116d85d7e1b4c2e6f70b496e3f29Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$260,403

Program and phase

STTR · Phase I

Award year

2018

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
RITHIM BIOLOGICS INC.
Proposal award date
2018-08-15
Contract end date
2019-08-14
UEI
R8S7GFCEVKB3
Solicitation number
PAR17-036
Topic code
NCATS

Research abstract

ABSTRACT Atrial fibrillationAFis the most common rhythm disturbance in the US and other developed countriesAF significantly affects the lives of the afflictedcausing symptoms that range from palpitations to fatigueweakness and activity intoleranceand substantially increasing the risks of strokecongestive heart failure and deathThe impact on public health is substantialwith more thanhospital admissions per year and $billion in healthcare costsAdding to the problems caused by AF is the lack of safe and effective therapies for this rhythm disorderPharmacotherapy for AF has a long history of poor efficacy and potentially lethal side effectsAblation strategies are making inroads in paroxysmal AFbut they are longdifficult procedures with less than optimal success rates and too frequent adverse eventsWe propose gene therapy as a new strategy to treat AFWe have published efficacy and safety data in a pig model of AF showing that interventions to prevent or reverse electrical and structural remodeling can eliminate the ability of the atria to fibrillateTo dateour atrial gene painting delivery method has required chest opening surgery which will ultimately limit clinical utilityHerewe propose development of a delivery catheter that will allow atrial gene painting from a percutaneous approach to the pericardial spaceTo develop this catheterwe propose the following specific aimsto verify performance of the gene painting catheter in bench top testingto confirm complete and specific atrial painting with the percutaneous catheter in acute animal studiesSuccessful completion of these aims will provide critical design and feasibility data that will move us toward our ultimate goal of curing AF with gene therapy Project Narrative Atrial fibrillationAFis the most common rhythm disturbance in the US and other developed countriesAF significantly affects the lives of the afflictedcausing symptoms that range from palpitations to fatigueweakness and activity intoleranceand substantially increasing the risks of strokecongestive heart failure and deathThe impact on public health is substantialwith more thanhospital admissions per year and $billion in added healthcare costsAdding to the problems caused by AF is the lack of safe and effective therapies for this rhythm disorderPharmacotherapy for AF has a long history of poor efficacy and potentially lethal side effectsNewer ablation strategies are making inroads in paroxysmal AFbut they are longdifficult procedures with less than optimal success rates and too frequent adverse eventsThis proposal focuses on developing gene therapy to treat and potentially cure AFWe have published efficacy and safety data showing that gene therapies can eliminate AFTo dateall of our data have been acquired using an atrial gene painting method that requires open chest surgeryIn this proposalwe will develop a catheter that will allow percutaneous access to the pericardium for atrial gene paintingThis advance will substantially increase clinical utility of the atrial gene painting method

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

3 SBIR/STTR records share this UEI (2018–2025). Reported award amounts total $1,650,317. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.